| PRECLINICAL | evidence | GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists may decrease biologic initiation in hidradenitis suppurativa: A TriNetX retrospective analysis. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Acute liver injury associated with tirzepatide: An unexpected adverse event warranting clinical attention. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | EBM BLS: Tirzepatide Leads to Resolution of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Without Worsening of Fibrosis. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Obesity Management: Pharmacotherapy. | Tirzepatide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Evaluating the antidepressant effects of tirzepatide on unpredictable chronic mild stress-induced depression in Swiss Albino mice. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Systemic Pharmacokinetic Principles of Therapeutic Peptides. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Targeting Cellulite as a Metabolic-Dermal Interface: Effects of Tirzepatide and a Multi-Pathway Topical Therapy (G21) in a 12-Month Observational Study. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Effects of Tirzepatide on Body Composition, Metabolic Parameters, and Sleep Outcomes: A Real-World One-Year Prospective Study. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. | Tirzepatide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Tirzepatide-Associated Euglycemic Diabetic Ketoacidosis in the Absence of Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report. | Mounjaro | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials. | Tirzepatide | Weight & fat loss · n = 20015 | 2026-04-01 |
| PRECLINICAL | evidence | Real world tirzepatide treatment for fatty liver disease. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions. | Tirzepatide | Liver health | 2026-04-01 |
| PRECLINICAL | evidence | Cost-Effectiveness of Highly Effective Glucose-Lowering Agents: Do Current Practices Optimize Clinical and Economic Outcomes? | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | The Necessity of POMC and MC3R Analysis in the First-Level Diagnosis of Monogenic Obesity: The Experience of Two Italian Centers. | Tirzepatide | Weight & fat loss | 2026-03-31 |
| PRECLINICAL | evidence | GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs. | Tirzepatide | — | 2026-03-30 |
| PRECLINICAL | evidence | Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review. | Tirzepatide | — | 2026-03-30 |
| PRECLINICAL | evidence | Obesity and Heart Failure: Introducing the Theme. | Tirzepatide | — | 2026-03-30 |
| PRECLINICAL | evidence | Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis. | Tirzepatide | — | 2026-03-29 |
| PRECLINICAL | evidence | Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. | Tirzepatide | — | 2026-03-28 |
| PRECLINICAL | evidence | Prevalence of Obesity Medications in the Military Health System: An Update from 2022. | Zepbound | — | 2026-03-27 |
| PRECLINICAL | evidence | Tirzepatide during Ramadan in people with obesity without diabetes: A critical knowledge gap. | Tirzepatide | — | 2026-03-27 |
| PRECLINICAL | evidence | Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects. | Tirzepatide | — | 2026-03-27 |
| PRECLINICAL | evidence | Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-03-27 |
| PRECLINICAL | evidence | The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis. | Tirzepatide | Lipid & cardiovascular markers · n = 8043 | 2026-03-27 |
| PRECLINICAL | evidence | Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. | Tirzepatide | — | 2026-03-26 |
| PRECLINICAL | evidence | Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report. | Tirzepatide | — | 2026-03-26 |
| PRECLINICAL | evidence | Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance. | Tirzepatide | Glycemic control | 2026-03-25 |
| PRECLINICAL | evidence | Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus. | Tirzepatide | — | 2026-03-23 |
| PRECLINICAL | evidence | Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition. | Tirzepatide | — | 2026-03-23 |
| PRECLINICAL | evidence | A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists. | Tirzepatide | — | 2026-03-23 |
| PRECLINICAL | evidence | Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial. | Tirzepatide | — | 2026-03-23 |